key: cord-0770279-0zoly1f2
authors: Gillies, Malcolm B.; Burgner, David P.; Ivancic, Lorraine; Nassar, Natasha; Miller, Jessica E.; Sullivan, Sheena G.; Todd, Isobel M. F.; Pearson, Sallie‐Anne; Schaffer, Andrea L.; Zoega, Helga
title: Changes in antibiotic prescribing following COVID‐19 restrictions: Lessons for post‐pandemic antibiotic stewardship
date: 2021-08-17
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.15000
sha: e80226e173eb13271afefb37c1f8e12aac214aa6
doc_id: 770279
cord_uid: 0zoly1f2

AIMS: Public health responses to reduce SARS‐CoV‐2 transmission have profoundly affected the epidemiology and management of other infections. We examined the impact of COVID‐19 restrictions on antibiotic dispensing in Australia. METHODS: We used national claims data to investigate antibiotic dispensing trends from November 2015 to October 2020 and whether changes reflected reductions in primary care consultations. We used interrupted time series analysis to quantify changes in monthly antibiotic dispensing and face‐to‐face and telehealth GP consultations and examined changes by recipient age, pharmacy State and prescriber specialty. RESULTS: Over the study period, an estimated 19 921 370 people had 125 495 137 antibiotic dispensings, 71% prescribed by GPs. Following COVID‐19 restrictions, we observed a sustained 36% (95% CI: 33–40%) reduction in antibiotic dispensings from April 2020. Antibiotics recommended for managing respiratory tract infections showed large reductions (range 51–69%), whereas those recommended for non‐respiratory infections were unchanged. Dispensings prescribed by GPs decreased from 63.5 per 1000 population for April–October 2019 to 37.0 per 1000 for April–October 2020. Total GP consultation rates remained stable, but from April 2020, 31% of consultations were telehealth. CONCLUSION: In a setting with a low COVID‐19 incidence, restrictions were associated with a substantial reduction in community dispensings of antibiotics primarily used to treat respiratory infections, coincident with reported reductions in respiratory viral infections. Our findings are informative for post‐pandemic antimicrobial stewardship and highlight the potential to reduce inappropriate prescribing by GPs and specialists for respiratory viral infections.

Public health responses to reduce SARS-CoV-2 transmission have profoundly affected the epidemiology of non-COVID-19 conditions.

Compared to the pre-pandemic period, there have been marked reductions in the incidence of hospitalised and non-hospitalised infectious diseases other than COVID-19. [1] [2] [3] [4] [5] [6] [7] In regions with high rates of SARS-CoV-2 infection, such as Europe and the United States, there have been reductions in community antibiotic prescribing following the introduction of COVID-19 restrictions in early 2020. [8] [9] [10] [11] [12] [13] [14] However, the underlying data are difficult to interpret as they reflect differing contributory and contemporaneous factors, including variation in public health restrictions and social policies, health care access, increasing use of telehealth and rates of SARS-CoV-2 infections.

Australia offers a unique opportunity to investigate changes in antibiotic prescribing during the pandemic; nationwide public health responses began in March 2020, with variation between States and Territories in the specific restrictions and their duration, but COVID-19 incidence has remained low. Leveraging national population-based claims data for medicines dispensed and primary care consultations, we evaluated the impact of COVID-19 restrictions on community antibiotic prescribing, considering changes by specific antibiotics, prescriber specialty, recipient age and jurisdiction. We hypothesised that the marked reduction in the transmission of respiratory viruses following COVID-19 restrictions would be reflected in a decrease in dispensing of antibiotics, especially those used to treat respiratory tract infections.

Australia has a universal healthcare system entitling all citizens and eligible residents to subsidised medicines through the Pharmaceutical Benefits Scheme (PBS) and subsidised medical services through the Medicare Benefits Scheme (MBS). 15 From 21 January 2020, the Australian government introduced its first response to mitigate SARS-CoV-2 transmission. Travel from highrisk countries was restricted starting 30 January, which culminated in border closures and mandatory 14-day hotel quarantine by 28 March 2020. Beginning mid-March, the Federal, State and Territory governments issued directions restricting the size of gatherings, visits to aged care and hospitals, elective surgeries, travel to remote communities, and closed dine-in, beauty and personal care services, and some public spaces. 16 Those who could work from home were required to do so, and schools were closed in some jurisdictions. In addition, some domestic borders were closed. Many of these restrictions were relaxed in May 2020. For most of the country (except Victoria), restrictions remained relaxed throughout the year, with the key exception of international travel. Australia has had a low incidence of COVID- 19: at 28 February   2021, there were a cumulative 22 354 locally acquired COVID-19 cases (88 per 100 000 population), with 87% of cases occurring in the State of Victoria (294 per 100 000) and 10% in New South Wales (27 per 100 000). 16 Cases peaked in mid-March and late-July, with the second outbreak occurring primarily in Victoria (July-November).

We drew on PBS dispensing claims from two national sources (see Data Availability Statement). First, we used monthly aggregate claims to analyse overall trends in antibiotic dispensing from 1 November 2015 to 30 October 2020. 17 Second, as these did not contain personlevel characteristics, we used claims for a 10% random sample of all PBS-eligible people from 1 November 2015 to 30 October 2020 for stratified analyses. When a subsidised medicine is dispensed in Australia, the administering pharmacy or hospital provides the government with data on the prescription dispensed, identity of the patient, prescribing doctor and supplying pharmacy. The two national data sources are different deidentified extracts of these dispensing claims data, either aggregated or a 10% sample of individual records. 15 The 10% PBS sample is a standard dataset provided by Australian Government Services Australia for analysis and is selected using the last digit of each person's randomly assigned unique identifier. To protect privacy, all dispensing dates are offset by ±14 days; the direction of the offset is the same for each individual. PBS dispensing claims do not include medicines dispensed in public hospitals and private dispensings, i.e. medicines for which the consumer pays the entire cost out-of-pocket.

We used national MBS claims data 18 to identify general practitioner (GP) attendances during the study period. These data provide counts of services processed each month by patient age group, State/Territory of service, and MBS item category. We categorised GP consultations as face-to-face and telehealth services according to broad MBS item categories (Table S1 in the Supporting Information).

We included all PBS-subsidised antibiotic medicines classified as In April 2020, changes were made to the PBS subsidy of amoxicillin, amoxicillin with clavulanic acid, cefalexin and roxithromycin. This included limiting the maximum quantities dispensed and eliminating refills. However, while many antibiotics are prescribed with refills, few are actually dispensed; for example, 8% of amoxicillin dispensings in 2012-13 were refills. 20 

We calculated monthly dispensing rates per 1000 population using the Australian Bureau of Statistics quarterly population, overall, and for the top ten antibiotics and the comparison medicines listed above.

We used interrupted time series (ITS) analysis to quantify changes in dispensing of antibiotics overall and of each of the top ten antibiotics, as well as of the comparison medicines. In the ITS analysis, we included variables representing a temporary increase in dispensing in March 2020 (pulse); and a level shift reduction in dispensing from 1 April to 30 October 2020. The level shift represents an immediate change that was sustained for the remainder of the study period. We included the temporary change in March due to reported increases in dispensing, likely due to stockpiling behaviour at the start of mitigation measures. 21, 22 To control for autocorrelation and seasonality, we used seasonal autoregressive integrative moving average (ARIMA) models.

We also conducted stratified descriptive analyses by age (0-1, 2-4, 5-9, 10-17, 18-64, 65+ years), pharmacy location (by State/ Territory), and prescriber (GP, dentist and other specialist). To determine the extent to which the April 2020 PBS changes had an impact on dispensing patterns, we also performed a stratified analysis for original and refill dispensings. Using the 10% PBS sample and the GP attendances data, we calculated the rate of antibiotic dispensing (GP-prescribed original dispensings only) per 100 consultations.

Analyses were conducted using R version 4.0.4 (R Project for Statistical Computing) and the tidyverts package. 

Using whole-of-population claims data, we observed a 17% (95% CI: Table 1 , Table S2 in the Supporting Information).

Among the ten most common antibiotics dispensed in 2019 (Table 1) , we observed the most pronounced reductions for roxithromycin 69% (95% CI: 64-73%), amoxicillin 53% (95% CI: 49-56%), and clarithromycin 51% (95% CI: 41-60%). There were no discernible reductions in flucloxacillin, metronidazole or trimethoprim dispensings (Table 1 and Figure S1 in the Supporting Information). For the comparison medicine class, purine-analogue antivirals, we observed a transient 27% (95% CI: 20-35%) increase in dispensing in March, followed by a 3% reduction (95% CI: 0-5%) from April onwards (Table S2 and Figure S2 in the Supporting Information).

Using 10% sample dispensing data, the observed trend in antibiotic dispensings was similar among prescriptions written by GPs and other specialists, but antibiotic prescribing by dentists rose sharply from 

Prior to March 2020, GP consultation rates increased annually by a mean of 1% (Figure 1) , with peaks in autumn and winter. The proportion of remote consultations (telehealth or video consultation) was less than 1%. Following COVID-19 restrictions, overall GP consultation rates increased initially in March by 16% (95% CI: 6-27%), and then from April onwards they returned to baseline and did not differ from predicted seasonal values, changing by 2% (95% CI: À5-10%).

The mean monthly proportion of telehealth consultations was 31%

for April-October ( Figure 

In this whole-of-population study, we observed a 36% reduction in data as our study, and observed the same pattern of increased dispensing in March 2020 followed by an overall decrease through to September 2020. They also concluded that the observations likely reflected decreased transmission of respiratory infections. 26 Other high-income countries have recorded similar changes in community antibiotic prescribing rates during the pandemic. In the US, the community dispensing rate for the ten most common antibiotics dropped by 13% to 56% in April, but returned to pre-pandemic levels by July 2020, except for antibiotics commonly used for respiratory infections, which showed sustained reductions. 11 In the Netherlands, there was a decrease in antibiotics for upper and lower respiratory infections, with no increase in observed complications from severe infections. 10 We found that the overall rates of GP consultations remained stable in Australia during the pandemic, albeit with a marked shift to telehealth. Remote assessment without clinical examination might have modified management decisions, but we were unable to link antibiotic prescribing patterns to GP consultation type. In England and the Netherlands, there were similar shifts from face-to-face to remote GP consultations 8, 10 and concern that telehealth consultations without clinical examination might lead to diagnostic uncertainty and inappropriate antibiotic prescribing. 27 We observed an increase in antibiotic prescribing by dental practitioners following the COVID-19 restrictions. Reduced access to dental care, particularly for surgical management of dental infections, is likely to have driven a switch to medical management. 28 Additionally, we saw initial increases in dispensings of ciclovirs following implementation of restrictions, suggesting patients were stockpiling in anticipation of shortage or stay-at-home orders; similar increases were also reported in Australia for medicines used to treat respiratory conditions, such as asthma or chronic obstructive pulmonary disease. 21 Australia is in the top quarter of countries for antibiotic use, compared with European countries and Canada. 29 Inappropriate antibiotic prescribing contrary to clinical guidelines is prevalent in both hospitals and the community in many countries and is a major driver of antimicrobial resistance. 30 Unnecessary antibiotics for viral respiratory infections managed in the community are a particular concern and a target for interventions; inappropriate prescribing for viral upper and lower respiratory tract infections has been estimated to account for roughly 40% of antibiotics prescribed by Australian GPs. 29, 31 These observations are consistent with our finding of a sharp decrease in antibiotic prescription rates during the COVID-19 pandemic, despite stable rates of GP consultations, given the reported falls in the incidence of viral respiratory tract infections cited above.

Strengths of our study include the analysis of total population claims data and person-level dispensing data from a random 10% of the population, allowing stratified analyses by age and practitioner type. We used robust interrupted time series methods to estimate the changes in antibiotic use at the population level, adjusting for historical trends and seasonal variation. We incorporated national data on the number and type of GP consultations, indicating that reduced health care access was unlikely to explain the reduction in antibiotic dispensings.

A prior Australian study did not use interrupted time series methods, person-level claims data or data on GP consultations. 26 Australia had a comparatively low COVID-19 incidence and high rates of SARS-CoV-2 testing. In contrast to high incidence settings, GPs did not need to treat COVID-19 patients in the community. 32 Our study limitations include a lack of information about the reason for consultation and indication for prescribing, as well as the lack of a link between individual consultation and dispensing records; therefore, we cannot determine with certainty the relative contribution of infection rates, patient presentation rates and GP management decisions to the reduction in antibiotic dispensing. We also lacked data on prescriptions that were not subsidised by the PBS; however, historical data suggest these are a small proportion of dispensed antibiotics. 29 Due to perturbation of dates in the PBS 10% sample data, we were unable to investigate differences due to State-by-State response measures in detail. Finally, new prescribing restrictions for selected PBS-listed antibiotics from 1 April 2020 may have reduced rates of dispensing. However, we found that the reductions in original and refill dispensings were similar.

Following measures to mitigate SARS-CoV-2 transmission, we observed substantial reductions in community dispensings of antibiotics primarily used to treat respiratory infections, in a setting with a low COVID-19 incidence. These reductions correspond to reported drops in respiratory viral infections and notifications; they were not accompanied by a decline in primary care consultations. The 

Impact of COVID-19 on healthcare

Decreased incidence of enterovirus and norovirus infections during the COVID-19 pandemic

Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses

The impact of COVID-19 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter

COVID-19 pandemic: Impact caused by school closure and national lockdown on pediatric visits and admissions for viral and non-viral infections, a time series analysis

Decreased influenza activity during the COVID-19 pandemic-United States

Changes in infectionrelated hospitalisations in children following pandemic restrictions: an interrupted time-series analysis of total population data

Antibiotic prescribing in general practice during COVID-19

Impact of the COVID-19 pandemic on community antibiotic prescribing in Scotland

Impact of the COVID-19 pandemic on antibiotic prescribing for common infections in The Netherlands: a primary care-based observational cohort study

Impact of the coronavirus disease 2019 pandemic on outpatient antibiotic prescriptions in the United States

Use of antibiotics during the COVID-19 pandemic

Effect of the coronavirus disease 2019 pandemic on antibiotic use in primary care

Antimicrobial stewardship in the UK during the COVID-19 pandemic: a population-based cohort study and interrupted time-series analysis

The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers

Reporting period ending 28

Australian Government Department of Health. PBS and RPBS Section 85 Date of Supply Data

Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Pharmaceutical Society of Australia, Royal Australian College of General Practitioners. Australian Medicines Handbook

Australian Government Department of Health

Australian Institute of Health and Welfare. Impacts of COVID-19 on Medicare Benefits Scheme and Pharmaceutical Benefits Scheme service use, Summary. Australian Institute of Health and Welfare

Increased dispensing of prescription medications in Australia early in the COVID-19 pandemic

Therapeutic Guidelines Ltd. eTG complete: Therapeutic Guidelines

Antibiotic prescribing for respiratory infections: a cross-sectional analysis of the ReCEnT study exploring the habits of early-career doctors in primary care

Insights into the impact of COVID-19 on household travel and activities in Australia-the early days under restrictions

National changes in outpatient systemic antibiotic use during the coronavirus disease 2019 pandemic in Australia

Impact of remote consultations on antibiotic prescribing in primary health care: systematic review

Trends in dental medication prescribing in Australia during the COVID-19 pandemic

AURA 2019: Third Australian Report on Antimicrobial Use and Resistance in Human Health. ACSQHC

Antibiotics for acute respiratory infections in general practice: comparison of prescribing rates with guideline recommendations

PRINCIPLE trial demonstrates scope for in-pandemic improvement in primary care antibiotic stewardship. BJGP Open

Changes in antibiotic prescribing following COVID-19 restrictions: Lessons for post-pandemic antibiotic stewardship

We thank the Australian Government Services Australia for providing the data and Melisa Litchfield for assisting with data access and ethics approval. This work was supported by the National Health and Medi- 

Helga Zoega https://orcid.org/0000-0003-0761-9028